chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Big patch; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of patchy rash in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced patchy rash (Verbatim: Big patch). The outcome of the patchy rash was not reported.   It was unknown if the reporter considered the patchy rash to be related to Shingles vaccine.     It was unknown if the company considered the patchy rash to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 08-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that luckily, he/she received Shingles vaccine. The patient stated that when he/she received Shingles vaccine it was not very big patch. Follow-up would not possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Asthenia
Clinical narrative: Weakening disease; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of weakness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced weakness (Verbatim: Weakening disease). The outcome of the weakness was not recovered/not resolved.   It was unknown if the reporter considered the weakness to be related to Shingles vaccine.     It was unknown if the company considered the weakness to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 08-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that he/she received second dose of Shingles vaccine and the vaccine gave him/her a weakening disease which was still have him/her 9 months later. Follow-up would not possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Pain in extremity
Clinical narrative: Arm is already sore; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 08-MAR-2023, the patient received Shingles vaccine. On 08-MAR-2023, less than a day after receiving Shingles vaccine, the patient experienced pain in arm (Verbatim: Arm is already sore). The outcome of the pain in arm was not reported.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine.     It was unknown if the company considered the pain in arm to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 08-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that he/she received Shingles vaccine just today and his/her arm was already sore. The patient stated that what he/she have seen it was better than the shingles. Follow-up would not possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Pain in extremity
Clinical narrative: Soreness in the arm not too bad; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced pain in arm (Verbatim: Soreness in the arm not too bad).The outcome of the pain in arm was not reported.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine.   It was unknown if the company considered the pain in arm to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 09-MAR-2023 This case was reported by a patient via interactive digital media. The patient experienced a little soreness in the arm but not too bad. The follow up would not possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Pain in extremity
Clinical narrative: sore arm; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced pain in arm (Verbatim: sore arm).The outcome of the pain in arm was not reported.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine.   It was unknown if the company considered the pain in arm to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 09-MAR-2023 This case was reported by a patient via interactive digital media. The patient stated that so far, he/she had no complications other than a sore arm. The follow up would not possible as no contact details were available.
Age: 82.0
Sex: F
Vaccine: VARZOS
Symptoms: Burning sensation, Herpes zoster, Pruritus
Clinical narrative: Two shingles episodes, went down nerve 3 inches; itching spot; burning spot; This non-serious case was reported by a nurse via call center representative and described the occurrence of shingles in a 82-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (prior shingles outbreaks).   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular, left deltoid). On an unknown date, 1 week after receiving Shingrix, [the patient experienced shingles (Verbatim: Two shingles episodes, went down nerve 3 inches), pruritus (Verbatim: itching spot) and burning sensation (Verbatim: burning spot).         The patient was treated with acyclovir (Zovirax) and acyclovir (Zovirax Ointment). The outcome of the shingles, pruritus and burning sensation were recovered/resolved.   It was unknown if the reporter considered the shingles, pruritus and burning sensation to be related to Shingrix.     It was unknown if the company considered the shingles, pruritus and burning sensation to be related to Shingrix.   Additional Information: GSK Receipt Date: 06-MAR-2023 The reporter was the patient and she was a (retired) nurse.  She reported that she had Shingrix shot on an unknown date around January 2023 or sometime in late Jan/Feb 2023.  She did not have the exact date with her at the time of the call. She did not have the lot number but did provide her pharmacy's contact information which would have that information on record.  About a week later, developed shingles on her left buttock that went down her nerve for about 3 inches. She was treated with Zovirax pills and Zovirax ointment and it went away.  Two weeks later the shingles episode came back again.  She indicated that it was not a full blown case it was just a spot that itched and burned.  These events was resolved.  She had not received Shingrix shot 2. She was a nurse transferred her to GSK medical information.  It appears she called back and spoke to a different GSK-MI agent who may not have been aware that The reporter was already filing a report.  The reporter was consented to follow up. This case has been linked with the case US2023035551, reported by the same reporter.; Sender's Comments:  US-GSK-US2023035551:Same reporter
Age: 1.0
Sex: M
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Expired Havrix administered; This non-serious case was reported by a physician via call center representative and described the occurrence of expired vaccine used in a 12-month-old male patient who received HAV (Havrix) (batch number T57F3, expiry date 16-FEB-2023) for prophylaxis.   On 06-MAR-2023, the patient received the 1st dose of Havrix. On 06-MAR-2023, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: Expired Havrix administered).  The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 06-MAR-2023 The reporter reported that a dose of Havrix that was expired on 16th February 2023 was inadvertently administered to the patient. The reporter did consent to follow up. The patient received a Havrix vaccine which was already expired, which led to expired vaccine used.
Sex: U
Vaccine: RV1
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: diluent other than the one supplied by GSK; diluent other than the one supplied by GSK; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Rota (Rotarix lyophilized formulation) for prophylaxis.   On an unknown date, the patient received Rotarix lyophilized formulation. On an unknown date, an unknown time after receiving Rotarix lyophilized formulation, the patient experienced wrong solution used in drug reconstitution (Verbatim: diluent other than the one supplied by GSK) and inappropriate dose of vaccine administered (Verbatim: diluent other than the one supplied by GSK). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 06-MAR-2023 The reporter stated that he/she understood lyophilized Rotarix should be reconstituted with the provided diluent but what would be the consequence if it was reconstituted with sterile water or normal saline instead.  The reporter wanted to know would the dose still be effective or it should be repeated. Adverse event was completed as conservative.  The reporter consented to follow up. The reporter stated that he/she understood lyophilized Rotarix should be reconstituted with the provided diluent but what would be the consequence if it was reconstituted with sterile water, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.
Age: 16.0
Sex: M
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: given Vx reconstituted with sterile water; given Vx reconstituted with sterile water; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA756A, expiry date 31-OCT-2023) for prophylaxis.   On 02-MAR-2023, the patient received Menveo. On 02-MAR-2023, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: given Vx reconstituted with sterile water) and inappropriate dose of vaccine administered (Verbatim: given Vx reconstituted with sterile water). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 07-MAR-2023 The nurse reported that the patient received a dose of Menveo that was reconstituted with sterile water. The adverse event contains all reported information. The reporter consented to follow up. The patient received dose of Menveo that was reconstituted with sterile water, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.
Age: 1.0
Sex: F
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration
Clinical narrative: 1st dose 12Oct2022, 2nd 06Mar2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 18-month-old female patient who received HAV (Havrix) (batch number 3397T, expiry date 07-OCT-2024) for prophylaxis.   Concomitant products included HEPATITIS A VACCINE (HAVRIX).   On 06-MAR-2023, the patient received the 2nd dose of Havrix. On 06-MAR-2023, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: 1st dose 12Oct2022, 2nd 06Mar2023). The outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 7-Mar-2023 The clinic supervisor reported that the patient received first dose at 13 months of age and then was given the second dose at her 18 month visit. Both doses were given from same lot number. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. The patient received second dose of Havrix earlier than the recommended interval, which led to shortening of vaccine schedule.
Sex: M
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Had vaccination series and shingles/suspected vaccination failure; Shingles every 6 months; This serious case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a elderly male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Had vaccination series and shingles/suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles every 6 months). The outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix and Shingrix.   Additional Information: GSK receipt date: 13-Mar-2023 The patient stated that he had the shingrix vaccination  series approximately 2 years ago and he had confirmed cases of shingles approximately every 6  months since receiving the vaccination series (no further information was known). The patient did not have an appointed primary care physician, he was assigned a different primary care physician with each visit. This case was considered as suspected vaccination failure since the details regarding the time to onset and laboratory confirmation of shingles were unknown at the time of reporting. The reporter consented to follow-up.
Sex: F
Vaccine: UNK, UNK
Symptoms: Incomplete course of vaccination, Pain, Pyrexia, Syncope, Vomiting
Clinical narrative: Fainted; Body aches; Vomiting; Fever; never received her second dose; This serious case was reported by a consumer via patient support programs and described the occurrence of fainting in a 64-year-old female patient who received Herpes zoster (Hz/su + AS01B) for prophylaxis.   Co-suspect products included Herpes zoster (Hz/su + AS01B) for prophylaxis.   On an unknown date, the patient received the 1st dose of Hz/su + AS01B and the 2nd dose of Hz/su + AS01B. On an unknown date, an unknown time after receiving Hz/su + AS01B and not applicable after receiving Hz/su + AS01B, [the patient experienced fainting (Verbatim: Fainted) (serious criteria GSK medically significant), general body pain (Verbatim: Body aches), vomiting (Verbatim: Vomiting), fever (Verbatim: Fever) and incomplete course of vaccination (Verbatim: never received her second dose).         The outcome of the fainting, general body pain, vomiting, fever and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the fainting, general body pain, vomiting and fever to be related to Hz/su + AS01B.   The company considered the fainting, general body pain, vomiting and fever to be unrelated to Hz/su + AS01B.   Additional Information: GSK Receipt Date: 13-MAR-2023 The reporter self-reported this case patient. This report was received when speaking with the customer during an outbound call for the support program.  The patient received her first dose of the Shingrix vaccine in either January 2020 or 2021.  The patient stated after her first dose she experienced vomiting, body aches, fever, and fainted. Reporter provided permission to contact healthcare professional. The reporter was consented to follow up. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Seasonal allergy
Clinical narrative: HAY FEVER; This spontaneous report received from a patient concerned an 8 decade old white male of an unspecified ethnicity. The patient's weight was 165 pounds, and height was 71 inches. The patient's concurrent conditions included: hay fever, and sudafed allergy (wigs him out terribly). The patient previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin, batch number and expiry date were not reported) dose was not reported, 1 total administered on an unspecified date in APR-2021 for covid-19 prophylaxis. On an unspecified date, the patient experienced hay fever (Dose number in series 1). The patient received booster dose with covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin, batch number and expiry date were not reported) dose was not reported, 1 total administered on an unspecified date in FEB-2022 for covid-19 prophylaxis. Age at time of vaccination 72 years old. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced recurrence of hay fever with lesser extent. (Dose number in series 2). Patient mentioned he only had to do acupuncture once for hay fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of hay fever was not reported. This report was non-serious. This case, involving the same patient is linked to 20230334821 (Dose number in series 1).
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 antibody test, SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: COVID-19 VIRUS TEST POSITIVE; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced covid-19 virus test positive. Laboratory data (dates unspecified) included: COVID-19 antibody test Positive, Positive, and COVID-19 virus test Positive. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of covid-19 virus test positive was not reported. This report was non-serious.
Age: 44.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Error: Expired Product Administered-
Age: 47.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Error: Expired Product Administered-
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Diarrhoea, Injection site erythema, Injection site pruritus, Lethargy, Rash
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Diarrhea-Medium, Systemic: Exhaustion / Lethargy-Medium, Additional Details: She states that the symptoms started on 3/13/23 the night of her immunization, and the itchiness is getting better now but the redness it still there and she is still lethargic.
Age: 86.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Pfizer  1/19/21  EL3249 dose 2 Pfizer  2/9/21  EL9265 dose 3 Pfizer  12/16/21  33130BA
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram pulmonary normal, Asthenia, Atelectasis, Blood culture negative, Blood lactic acid normal
Clinical narrative: Discharge summary "Patient is a 57 YO female with a PMHx of chronic respiratory failure on 2 L O2 at baseline, COPD, MDD, anxiety, metabolic stone disease, neurogenic bladder, multiple urinary tract infections (follows with Urology as noted below), chronic foley, HLD, MS (bed-bound at baseline, only has use of left arm/hand), chronic constipation, GERD, and insomnia who presented to the ED on 3/15/23 with fever, shortness of breath, weakness and nonproductive cough for one day. She tested positive for COVID-19 on 3/14/23.      Patient was brought to the ED on 3L O2. Her oxygen saturation dropped to 88% and she was titrated up to 5L. She had a fever of 102.5 F and was tachycardic up to 135. Rapid COVID test was positive. Patient did not have a leukocytosis. Lactic Acid was not elevated. Procalcitonin was elevated to 0.4. D-dimer was elevated to 650. Chest X-ray demonstrated chronic left lower lobe atelectasis or pneumonic scarring. CTA pulm was negative for embolism or definite pneumonia. Left greater than right posterior airspace disease favoring atelectasis. Pneumonia, such as aspiration pneumonia possible. EKG demonstrated sinus tachycardia with ST and T wave inversion in the inferior leads. Patient was administered Ofirmev, fluid bolus and Unasyn. Patient was accepted for admission to the hospitalist team.    Patient was treated with Decadon, DuoNebs, and Mucinex, and she was weaned off of supplemental oxygen as tolerated.  IV Unasyn was continued. UA results were indicative of UTI and culture grew gram negative rods. Blood cultures had no growth. Patient had no further fevers during her hospital stay. She was weaned off of oxygen completely and was saturating 98% on room air. On evaluation on the morning of 3/16/23 patient admitted to being back to her baseline. She was feeling well and requesting to go back home. As vitals and labs were stable patient was discharged home with 5 days of Augmentin to treat her UTI. "
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Condition aggravated, Cough, Culture urine positive
Clinical narrative: Discharge summary "Patient is a 57 YO female with a PMHx of chronic respiratory failure on 2 L O2 at baseline, COPD, MDD, anxiety, metabolic stone disease, neurogenic bladder, multiple urinary tract infections (follows with Urology as noted below), chronic foley, HLD, MS (bed-bound at baseline, only has use of left arm/hand), chronic constipation, GERD, and insomnia who presented to the ED on 3/15/23 with fever, shortness of breath, weakness and nonproductive cough for one day. She tested positive for COVID-19 on 3/14/23.      Patient was brought to the ED on 3L O2. Her oxygen saturation dropped to 88% and she was titrated up to 5L. She had a fever of 102.5 F and was tachycardic up to 135. Rapid COVID test was positive. Patient did not have a leukocytosis. Lactic Acid was not elevated. Procalcitonin was elevated to 0.4. D-dimer was elevated to 650. Chest X-ray demonstrated chronic left lower lobe atelectasis or pneumonic scarring. CTA pulm was negative for embolism or definite pneumonia. Left greater than right posterior airspace disease favoring atelectasis. Pneumonia, such as aspiration pneumonia possible. EKG demonstrated sinus tachycardia with ST and T wave inversion in the inferior leads. Patient was administered Ofirmev, fluid bolus and Unasyn. Patient was accepted for admission to the hospitalist team.    Patient was treated with Decadon, DuoNebs, and Mucinex, and she was weaned off of supplemental oxygen as tolerated.  IV Unasyn was continued. UA results were indicative of UTI and culture grew gram negative rods. Blood cultures had no growth. Patient had no further fevers during her hospital stay. She was weaned off of oxygen completely and was saturating 98% on room air. On evaluation on the morning of 3/16/23 patient admitted to being back to her baseline. She was feeling well and requesting to go back home. As vitals and labs were stable patient was discharged home with 5 days of Augmentin to treat her UTI. "
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Electrocardiogram ST segment abnormal, Electrocardiogram T wave inversion, Electrocardiogram abnormal, Fibrin D dimer
Clinical narrative: Discharge summary "Patient is a 57 YO female with a PMHx of chronic respiratory failure on 2 L O2 at baseline, COPD, MDD, anxiety, metabolic stone disease, neurogenic bladder, multiple urinary tract infections (follows with Urology as noted below), chronic foley, HLD, MS (bed-bound at baseline, only has use of left arm/hand), chronic constipation, GERD, and insomnia who presented to the ED on 3/15/23 with fever, shortness of breath, weakness and nonproductive cough for one day. She tested positive for COVID-19 on 3/14/23.      Patient was brought to the ED on 3L O2. Her oxygen saturation dropped to 88% and she was titrated up to 5L. She had a fever of 102.5 F and was tachycardic up to 135. Rapid COVID test was positive. Patient did not have a leukocytosis. Lactic Acid was not elevated. Procalcitonin was elevated to 0.4. D-dimer was elevated to 650. Chest X-ray demonstrated chronic left lower lobe atelectasis or pneumonic scarring. CTA pulm was negative for embolism or definite pneumonia. Left greater than right posterior airspace disease favoring atelectasis. Pneumonia, such as aspiration pneumonia possible. EKG demonstrated sinus tachycardia with ST and T wave inversion in the inferior leads. Patient was administered Ofirmev, fluid bolus and Unasyn. Patient was accepted for admission to the hospitalist team.    Patient was treated with Decadon, DuoNebs, and Mucinex, and she was weaned off of supplemental oxygen as tolerated.  IV Unasyn was continued. UA results were indicative of UTI and culture grew gram negative rods. Blood cultures had no growth. Patient had no further fevers during her hospital stay. She was weaned off of oxygen completely and was saturating 98% on room air. On evaluation on the morning of 3/16/23 patient admitted to being back to her baseline. She was feeling well and requesting to go back home. As vitals and labs were stable patient was discharged home with 5 days of Augmentin to treat her UTI. "
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Lung disorder, Oxygen saturation decreased, Procalcitonin, Pulmonary fibrosis, Pyrexia
Clinical narrative: Discharge summary "Patient is a 57 YO female with a PMHx of chronic respiratory failure on 2 L O2 at baseline, COPD, MDD, anxiety, metabolic stone disease, neurogenic bladder, multiple urinary tract infections (follows with Urology as noted below), chronic foley, HLD, MS (bed-bound at baseline, only has use of left arm/hand), chronic constipation, GERD, and insomnia who presented to the ED on 3/15/23 with fever, shortness of breath, weakness and nonproductive cough for one day. She tested positive for COVID-19 on 3/14/23.      Patient was brought to the ED on 3L O2. Her oxygen saturation dropped to 88% and she was titrated up to 5L. She had a fever of 102.5 F and was tachycardic up to 135. Rapid COVID test was positive. Patient did not have a leukocytosis. Lactic Acid was not elevated. Procalcitonin was elevated to 0.4. D-dimer was elevated to 650. Chest X-ray demonstrated chronic left lower lobe atelectasis or pneumonic scarring. CTA pulm was negative for embolism or definite pneumonia. Left greater than right posterior airspace disease favoring atelectasis. Pneumonia, such as aspiration pneumonia possible. EKG demonstrated sinus tachycardia with ST and T wave inversion in the inferior leads. Patient was administered Ofirmev, fluid bolus and Unasyn. Patient was accepted for admission to the hospitalist team.    Patient was treated with Decadon, DuoNebs, and Mucinex, and she was weaned off of supplemental oxygen as tolerated.  IV Unasyn was continued. UA results were indicative of UTI and culture grew gram negative rods. Blood cultures had no growth. Patient had no further fevers during her hospital stay. She was weaned off of oxygen completely and was saturating 98% on room air. On evaluation on the morning of 3/16/23 patient admitted to being back to her baseline. She was feeling well and requesting to go back home. As vitals and labs were stable patient was discharged home with 5 days of Augmentin to treat her UTI. "
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: SARS-CoV-2 test positive, Sinus tachycardia, Tachycardia, Urinary tract infection, Urine analysis abnormal
Clinical narrative: Discharge summary "Patient is a 57 YO female with a PMHx of chronic respiratory failure on 2 L O2 at baseline, COPD, MDD, anxiety, metabolic stone disease, neurogenic bladder, multiple urinary tract infections (follows with Urology as noted below), chronic foley, HLD, MS (bed-bound at baseline, only has use of left arm/hand), chronic constipation, GERD, and insomnia who presented to the ED on 3/15/23 with fever, shortness of breath, weakness and nonproductive cough for one day. She tested positive for COVID-19 on 3/14/23.      Patient was brought to the ED on 3L O2. Her oxygen saturation dropped to 88% and she was titrated up to 5L. She had a fever of 102.5 F and was tachycardic up to 135. Rapid COVID test was positive. Patient did not have a leukocytosis. Lactic Acid was not elevated. Procalcitonin was elevated to 0.4. D-dimer was elevated to 650. Chest X-ray demonstrated chronic left lower lobe atelectasis or pneumonic scarring. CTA pulm was negative for embolism or definite pneumonia. Left greater than right posterior airspace disease favoring atelectasis. Pneumonia, such as aspiration pneumonia possible. EKG demonstrated sinus tachycardia with ST and T wave inversion in the inferior leads. Patient was administered Ofirmev, fluid bolus and Unasyn. Patient was accepted for admission to the hospitalist team.    Patient was treated with Decadon, DuoNebs, and Mucinex, and she was weaned off of supplemental oxygen as tolerated.  IV Unasyn was continued. UA results were indicative of UTI and culture grew gram negative rods. Blood cultures had no growth. Patient had no further fevers during her hospital stay. She was weaned off of oxygen completely and was saturating 98% on room air. On evaluation on the morning of 3/16/23 patient admitted to being back to her baseline. She was feeling well and requesting to go back home. As vitals and labs were stable patient was discharged home with 5 days of Augmentin to treat her UTI. "
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal pain, Blood culture negative, Blood pressure increased, COVID-19, Chest pain
Clinical narrative: discharge summary "Hospital Course: 68 YO female with a history of  psoriatic arthritis on prednisone and methotrexate, DVT/PE on Eliquis, type 2 diabetes mellitus who presents with nausea, vomiting, diarrhea, chest/abdominal pain.  Found to have small-bowel obstruction.    SBO - resolved with NG tube decompression - Originally NPO. NG tube removed 03/16; pt tolerated low fiber, low residue diet, able to pass gas and stool - Home pain meds - PRN Zofran - General Surgery onboard, OK for D/C   COVID-19  Patient is not displaying respiratory symptoms at this time - Symptomatic management   HTN Acute pain may be contributing to elevated blood pressures - resume home amlodipine and losartan    HLD 10-year ASCVD risk is 28.4%. No statin therapy recorded in Home Meds.  - Initiate lipitor 40 mg   T2DM - Resume home oral diabetic medications   Fever, 03/15 - resolved  May have been 2/2 COVID-19 - 03/15 BCx NGTD   Plaque psoriasis Multiple joint pain, chronic' ?Psoriatic arthritis  - Sees Dr. (Rheumatology) - Followed by Dr. (Derm) for psoriasis who recommended initiation of Stelara - Reportedly taking Methotrexate 2.5 mg (5 pills weekly) and folic acid daily - Home Tacolnex ointment not on formulary - Restart home ibuprofen, Norco, methotrexate, and prednisone   Hypokalemia, resolved    History of pulmonary embolism, Nov 2021 Patient on Eliquis, Continue "
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Condition aggravated, Diarrhoea, Gastrointestinal tube insertion, Hypertension, Nausea
Clinical narrative: discharge summary "Hospital Course: 68 YO female with a history of  psoriatic arthritis on prednisone and methotrexate, DVT/PE on Eliquis, type 2 diabetes mellitus who presents with nausea, vomiting, diarrhea, chest/abdominal pain.  Found to have small-bowel obstruction.    SBO - resolved with NG tube decompression - Originally NPO. NG tube removed 03/16; pt tolerated low fiber, low residue diet, able to pass gas and stool - Home pain meds - PRN Zofran - General Surgery onboard, OK for D/C   COVID-19  Patient is not displaying respiratory symptoms at this time - Symptomatic management   HTN Acute pain may be contributing to elevated blood pressures - resume home amlodipine and losartan    HLD 10-year ASCVD risk is 28.4%. No statin therapy recorded in Home Meds.  - Initiate lipitor 40 mg   T2DM - Resume home oral diabetic medications   Fever, 03/15 - resolved  May have been 2/2 COVID-19 - 03/15 BCx NGTD   Plaque psoriasis Multiple joint pain, chronic' ?Psoriatic arthritis  - Sees Dr. (Rheumatology) - Followed by Dr. (Derm) for psoriasis who recommended initiation of Stelara - Reportedly taking Methotrexate 2.5 mg (5 pills weekly) and folic acid daily - Home Tacolnex ointment not on formulary - Restart home ibuprofen, Norco, methotrexate, and prednisone   Hypokalemia, resolved    History of pulmonary embolism, Nov 2021 Patient on Eliquis, Continue "
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nothing by mouth order, Pyrexia, SARS-CoV-2 test positive, Small intestinal obstruction, Vomiting
Clinical narrative: discharge summary "Hospital Course: 68 YO female with a history of  psoriatic arthritis on prednisone and methotrexate, DVT/PE on Eliquis, type 2 diabetes mellitus who presents with nausea, vomiting, diarrhea, chest/abdominal pain.  Found to have small-bowel obstruction.    SBO - resolved with NG tube decompression - Originally NPO. NG tube removed 03/16; pt tolerated low fiber, low residue diet, able to pass gas and stool - Home pain meds - PRN Zofran - General Surgery onboard, OK for D/C   COVID-19  Patient is not displaying respiratory symptoms at this time - Symptomatic management   HTN Acute pain may be contributing to elevated blood pressures - resume home amlodipine and losartan    HLD 10-year ASCVD risk is 28.4%. No statin therapy recorded in Home Meds.  - Initiate lipitor 40 mg   T2DM - Resume home oral diabetic medications   Fever, 03/15 - resolved  May have been 2/2 COVID-19 - 03/15 BCx NGTD   Plaque psoriasis Multiple joint pain, chronic' ?Psoriatic arthritis  - Sees Dr. (Rheumatology) - Followed by Dr. (Derm) for psoriasis who recommended initiation of Stelara - Reportedly taking Methotrexate 2.5 mg (5 pills weekly) and folic acid daily - Home Tacolnex ointment not on formulary - Restart home ibuprofen, Norco, methotrexate, and prednisone   Hypokalemia, resolved    History of pulmonary embolism, Nov 2021 Patient on Eliquis, Continue "
Age: 79.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Chronic obstructive pulmonary disease, Condition aggravated, Hypoxia, SARS-CoV-2 test positive
Clinical narrative: Brief Summary of Hospital Stay: 80-year-old female with a history of chronic obstructive pulmonary disease, HTN, T2DM who was admitted for acute hypoxia 2/2 to COVID-19 infection and likely COPD exacerbation. She was given a course of Remdesivir for 2 days, Ceftriaxone, and Prednisone. She was feeling better at time of discharge. She was sent home on 2L of oxygen. She was discharged to finish 2 more days of antibiotics with Cefdinir, and 7 more days of Prednisone. She was found to have soft BP's inpatient and was told to hold HCTZ until she sees PCP. She was discharged on home oxygen.     She needs to follow with PCP for management of care after inpatient stay.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Pyrexia, Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: I did not have a reaction to the vaccine. I had a runny nose with a fever a couple of days before testing positive. I tested positive for COVID-19 on 11/17/2022. I contacted my doctor, but I was not a candidate for Paxlovid because of heart issues. I was prescribed Molnupiravir which helped with my symptoms.
Age: 50.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pain in extremity, Product administered at inappropriate site
Clinical narrative: patient's mother explained patient complained injection seemed higher on her arm than normal and has been having arm pain ever since the injection.  her physician said she would need an mri to properly diagnose the root cause.
Age: 69.0
Sex: M
Vaccine: COVID19-2
Symptoms: Blepharitis, Eyelid pain, Pain
Clinical narrative: I had aches and pains for about a day after receiving the vaccine. I developed painful eyelids and it hurt to blink. I went to my doctor and was diagnosed with blepharitis. I was given a prescription for an topical antibiotic and a steroid. As of today, I am feeling better.
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Cough, Dyspnoea, Fatigue, Feeling abnormal
Clinical narrative: I was positive for COVID-19 on 18FEB2023, I was very achy and tired, coughing a lot and I had a hard time breathing. I had a very sore throat, congested and very stuffy. I contacted my doctor and she prescribed me PAXLOVID. Even after taking the medication I still was feeling terrible and I wasn't getting any better, she than prescribed me a steroids medication and started feeling a bit better.
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: Nasal congestion, Oropharyngeal pain, Pain, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: I was positive for COVID-19 on 18FEB2023, I was very achy and tired, coughing a lot and I had a hard time breathing. I had a very sore throat, congested and very stuffy. I contacted my doctor and she prescribed me PAXLOVID. Even after taking the medication I still was feeling terrible and I wasn't getting any better, she than prescribed me a steroids medication and started feeling a bit better.
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Nasopharyngitis, Oropharyngeal pain, SARS-CoV-2 test positive, Sinusitis
Clinical narrative: I had a sore after receiving the vaccine for about a day. I had cold like symptoms or a sinus infection in half of my head. I tested positive for COVID-19 on 01/17/2023. I had a telehealth visit with my doctor but did not get a prescription. I took TYLENOL to help with my symptoms.
Age: 14.0
Sex: M
Vaccine: HPV9
Symptoms: Erythema, Joint range of motion decreased, Pain, Skin warm, Swelling
Clinical narrative: VERY PAINFUL CAUSING LIMITED RANGE OF MOTION FOR FEW DAYS NOW AND REDNESS THAT EXTENDS DOWN INTO HIS SIDE AND IT IS SWOLLEN, SLIGHTLY WARM TO TOUCH
Age: 64.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, Cough, SARS-CoV-2 test positive
Clinical narrative: My wife had flu and tested positive for COVID-19; I did a COVID-19 test and I tested positive and keep testing positive for 2 weeks, with cough, I did a telehealth session with my doctor and gave me steroids for 10 days, basically kept the cough under control, but I still have it, it has been 10 weeks. I am no longer positive for COVID-19, but that's what happened.
Age: 74.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Decreased appetite, Headache, Nasopharyngitis, Pain
Clinical narrative: I tested negative for the first 2 days. I had symptoms of a head cold. By that night I had a fever of 102.0 and body aches. I also had a headache. I had not appetite for a couple of days. The fever lasted a day and a half. I was taking Tylenol. The head cold remained for about a week and a half. I was prescribed Paxlovid on the 3rd day. I have since recovered from all my symptoms.
Age: 74.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pyrexia, SARS-CoV-2 test positive
Clinical narrative: I tested negative for the first 2 days. I had symptoms of a head cold. By that night I had a fever of 102.0 and body aches. I also had a headache. I had not appetite for a couple of days. The fever lasted a day and a half. I was taking Tylenol. The head cold remained for about a week and a half. I was prescribed Paxlovid on the 3rd day. I have since recovered from all my symptoms.
Age: 1.08
Sex: F
Vaccine: HEPA, HIBV, MMRV, VARCEL
Symptoms: Extra dose administered, No adverse event
Clinical narrative: The patient received Proquad, and Varivax both at Well Child exam. The child's doctor and staff immediately notified the child's mother. The child did not have any reactions while in the clinic. Provider called the child's mother later in the evening to check on the child, and the child was well. This supervisor called the child's mother the next morning, and confirmed that the child was still doing well. Call placed to the Manugacturer, Merck, to verify next steps, who informed us there was no concerns.  Provider, and the child's mother were informed of this as well. The child's mother was aware to contact us at any time with any questions or concerns.
Age: 35.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect product formulation administered
Clinical narrative: Patient was given a bivalent vaccine instead of the monovalent vaccine for the initial dose of primary series
Age: 74.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Ageusia, Anosmia, COVID-19, Cough, Fatigue
Clinical narrative: Around 01/28/2023, I started with symptoms that I thought were a cold. I had a sore throat, coughing, fatigue, and a runny nose. I had a call from my daughter on 01/31/2023 informing me that she had tested positive for COVID-19. I went the next day, to an urgent care clinic. I tested positive for COVID-19, and they prescribed Paxlovid. I lost my sense of taste and smell. That lasted around three or four weeks, but it has returned now. I really didn't feel that bad throughout the whole thing.
Age: 74.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Nasopharyngitis, Oropharyngeal pain, Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: Around 01/28/2023, I started with symptoms that I thought were a cold. I had a sore throat, coughing, fatigue, and a runny nose. I had a call from my daughter on 01/31/2023 informing me that she had tested positive for COVID-19. I went the next day, to an urgent care clinic. I tested positive for COVID-19, and they prescribed Paxlovid. I lost my sense of taste and smell. That lasted around three or four weeks, but it has returned now. I really didn't feel that bad throughout the whole thing.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: hospitalization
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Laboratory test, Malaise
Clinical narrative: Symptom onset 3/13/23. Treatment includes admission with therapy, labs, and assessment.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Decreased appetite, Lacrimation increased, Rhinorrhoea, Vaccination site bruising, Vomiting
Clinical narrative: Patient with vomiting the day after receiving vaccines. Parents state that she vomited 4 times within 30 minutes the evening after receiving vaccines. Her appetite was poor for the next 2 days. They also described runny nose and watery eyes as well as bruising at one of the vaccine sites.  No other rash
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Asthenia, COVID-19, Cough, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: The adverse event was not due to the vaccinee, but I got COVID on Dec 30th, 2022. I saw the doctor to get Paxlovid. I had Cough, weakness and fever.
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: X-ray normal
Clinical narrative: The adverse event was not due to the vaccinee, but I got COVID on Dec 30th, 2022. I saw the doctor to get Paxlovid. I had Cough, weakness and fever.
Age: 68.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, Chills, Cough, Eye discharge, Muscular weakness
Clinical narrative: I started having a scratchy throat, coughing, a runny nose, I could feel congestion in my chest. I had some weakness in my legs, particularly in my calves. Within the first forty-eight hours I had chills. It was really strange, every day something new showed up. I took a home test late in the evening on February 28 that came back positive. I went to an emergency room on March 1 to confirm that my home test was correct. I was given a PCR COVID-19 test that came positive. I was prescribed molnupiravir antiviral, the next day I started having discharge coming from my eyes in the morning for two days. It wasn't like the "sleep" you wake up with sometimes it was very different. I still cough and still have some phlegm, but I feel like I have recovered. Today has been my best morning since March 1.
Age: 68.0
Sex: M
Vaccine: COVID19-2
Symptoms: Productive cough, Respiratory tract congestion, Rhinorrhoea, SARS-CoV-2 test positive, Throat irritation
Clinical narrative: I started having a scratchy throat, coughing, a runny nose, I could feel congestion in my chest. I had some weakness in my legs, particularly in my calves. Within the first forty-eight hours I had chills. It was really strange, every day something new showed up. I took a home test late in the evening on February 28 that came back positive. I went to an emergency room on March 1 to confirm that my home test was correct. I was given a PCR COVID-19 test that came positive. I was prescribed molnupiravir antiviral, the next day I started having discharge coming from my eyes in the morning for two days. It wasn't like the "sleep" you wake up with sometimes it was very different. I still cough and still have some phlegm, but I feel like I have recovered. Today has been my best morning since March 1.
Age: 89.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Unevaluable event
Clinical narrative: HOSPITALIZATION
Age: 72.0
Sex: M
Vaccine: COVID19-2, FLU4
Symptoms: COVID-19, Cough, Feeling hot, Insomnia, SARS-CoV-2 test positive
Clinical narrative: On 03/13/2023, around midday, I had a slight cough. I had great difficulty sleeping. I never had a fever, though I felt warm. The cough was the major thing. On 03/14/2023, I tested positive for COVID-19 at home. I spoke with the medical group and the told me to take SUDAFED and they prescribed a cough suppressant.
Age: 77.0
Sex: F
Vaccine: COVID19-2, FLUA4
Symptoms: COVID-19, Cough, Fatigue, SARS-CoV-2 test positive
Clinical narrative: I had  a positive COVID-19 test and called my doctor regarding Paxlovid which I picked up later that day and began taking it the next day or third day and took it for five days. My symptoms we dry cough and fatigue but I was able to due my daily activities. I stayed home and my Husband picked up my prescription and did the shopping . 15FEB2023 I was still testing positive on 18FEB2023 I tested negative.
Age: 34.0
Sex: F
Vaccine: COVID19-2
Symptoms: Astigmatism, Full blood count abnormal, Heart rate increased, Laboratory test normal, Magnetic resonance imaging normal
Clinical narrative: I started with leg pain after my vaccine. I am dealing with this now. I diagnosed with Lupus on 02-14-2023. I experienced migraines at night time, I have stigmatism, my heart rate goes up to 120-130BPM. I also had a complete blood work for Lupus. I continue to this day having leg pain and migraines.
Age: 34.0
Sex: F
Vaccine: COVID19-2
Symptoms: Migraine, Pain in extremity, Systemic lupus erythematosus, X-ray normal
Clinical narrative: I started with leg pain after my vaccine. I am dealing with this now. I diagnosed with Lupus on 02-14-2023. I experienced migraines at night time, I have stigmatism, my heart rate goes up to 120-130BPM. I also had a complete blood work for Lupus. I continue to this day having leg pain and migraines.